基于血液DNA甲基化测得的衰老速度与年龄相关认知障碍和痴呆的相关性
研究利用ADNI和FHS子代队列数据,检验三种DNA甲基化衰老算法与老年人认知障碍和痴呆的关联。ADNI(N=649)中第一、二代算法与认知障碍无一致关联,第三代DunedinPACE与阿尔茨海默病临床诊断(beta=0.28,95%CI 0.08-0.47)及较差的筛查和认知测试评分相关;FHS子代队列(N=2264)纵向分析证实DunedinPACE较快衰老速度与痴呆风险相关(HR=1.27,95%CI 1.07-1.49)。
要点
- 第一、二代DNA甲基化衰老时钟与认知障碍无一致关联。
- 第三代DunedinPACE与阿尔茨海默病临床诊断相关(beta=0.28,95%CI 0.08-0.47)。
- DunedinPACE较快衰老速度与痴呆风险相关(HR=1.27,95%CI 1.07-1.49)。
核心结论
- 第三代基于血液的DNA甲基化衰老测量可能有助于衡量个体衰老速度差异及认知下降风险,并用于评估延缓衰老的干预措施。
研究设计与样本
- 研究使用阿尔茨海默病神经影像学倡议(ADNI)和弗雷明汉心脏研究(FHS)子代队列数据,检验三种DNA甲基化年龄算法与认知障碍和痴呆的关联。
- ADNI分析纳入649人;FHS子代队列纵向分析纳入2264人。
主要发现
- ADNI中第一代(Horvath和Hannum时钟)和第二代(PhenoAge和GrimAge)DNA甲基化衰老测量与老年人认知障碍测量无一致关联。
- ADNI中DunedinPACE与阿尔茨海默病临床诊断相关(beta=0.28,95%CI 0.08-0.47)。
- ADNI中DunedinPACE与阿尔茨海默病/阿尔茨海默病及相关痴呆筛查测试较差评分相关(beta[稳健标准误]=-0.10[0.04]至0.08[0.04])。
- ADNI中DunedinPACE与认知测试较差评分相关(beta[稳健标准误]=-0.12[0.04]至0.10[0.03])。
- FHS子代队列纵向分析中,DunedinPACE测得的较快衰老速度与痴呆风险相关(HR=1.27,95%CI 1.07-1.49)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: DNA methylation algorithms are increasingly used to estimate biological aging; however, how these proposed measures of whole-organism biological aging relate to aging in the brain is not known. We used data from the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Framingham Heart Study (FHS) Offspring Cohort to test the association between blood-based DNA methylation measures of biological aging and cognitive impairment and dementia in older adults. METHODS: We tested 3 "generations" of DNA methylation age algorithms (first generation: Horvath and Hannum clocks; second generation: PhenoAge and GrimAge; and third generation: DunedinPACE, Dunedin Pace of Aging Calculated from the Epigenome) against the following measures of cognitive impairment in ADNI: clinical diagnosis of dementia and mild cognitive impairment, scores on Alzheimer disease (AD) / Alzheimer disease and related dementias (ADRD) screening tests (Alzheimer's Disease Assessment Scale, Mini-Mental State Examination, and Montreal Cognitive Assessment), and scores on cognitive tests (Rey Auditory Verbal Learning Test, Logical Memory test, and Trail Making Test). In an independent replication in the FHS Offspring Cohort, we further tested the longitudinal association between the DNA methylation algorithms and the risk of developing dementia. RESULTS: In ADNI (N = 649 individuals), the first-generation (Horvath and Hannum DNA methylation age clocks) and the second-generation (PhenoAge and GrimAge) DNA methylation measures of aging were not consistently associated with measures of cognitive impairment in older adults. By contrast, a third-generation measure of biological aging, DunedinPACE, was associated with clinical diagnosis of Alzheimer disease (beta [95% CI] = 0.28 [0.08-0.47]), poorer scores on Alzheimer disease/ADRD screening tests (beta [Robust SE] = -0.10 [0.04] to 0.08[0.04]), and cognitive tests (beta [Robust SE] = -0.12 [0.04] to 0.10 [0.03]). The association between faster pace of aging, as measured by DunedinPACE, and risk of developing dementia was confirmed in a longitudinal analysis of the FHS Offspring Cohort (N = 2,264 individuals, hazard ratio [95% CI] = 1.27 [1.07-1.49]). DISCUSSION: Third-generation blood-based DNA methylation measures of aging could prove valuable for measuring differences between individuals in the rate at which they age and in their risk for cognitive decline, and for evaluating interventions to slow aging.
引用
- Sugden K, Caspi A, Elliott ML, et al. Association of Pace of Aging Measured by Blood-Based DNA Methylation With Age-Related Cognitive Impairment and Dementia. Neurology. 2022. PMID: 35794023. doi:10.1212/WNL.0000000000200898
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。